First FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adolescents aged 12 – 17 years, broadening the population in which nipocalimab has been studied SAVANNAH, Ga., Oct. 15, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive results from the Phase 2/3 Vibrance-MG study of nipocalimab in anti-AChRa positive adolescents (aged 12 – 17 years) living with generalized myasthenia gravis (gMG). Study participants who were treated with nipocalimab plu ...

[Sales Performance Analysis](index=1&type=section&id=Supplementary%20Sales%20Data) The company reports solid sales growth driven by the U.S. market and strong performance in both core business segments [Sales by Geographic Area](index=1&type=section&id=Sales%20to%20customers%20by%20geographic%20area) Worldwide sales grew across both periods, led by strong performance in the U.S. market and offset by international currency headwinds Q3 2024 Sales by Geographic Area (in Millions) | Region | 2024 Sales | 2023 Sales | Total Change | Operational Change | | :--- | :--- | :--- | :--- | :--- | | U.S. | $12,909 | $11,996 | 7.6% | 7.6% | | International | $9,562 | $9,355 | 2.2% | 4.6% | | **Worldwide** | **$22,471** | **$21,351** | **5.2%** | **6.3%** | Nine Months 2024 Sales by Geographic Area (in Millions) | Region | 2024 Sales | 2023 Sales | Total Change | Operational Change | | :--- | :--- | :--- | :--- | :--- | | U.S. | $37,098 | $34,435 | 7.7% | 7.7% | | International | $29,203 | $29,329 | (0.4)% | 3.1% | | **Worldwide** | **$66,301** | **$63,764** | **4.0%** | **5.6%** | - Excluding the COVID-19 vaccine, worldwide sales growth was stronger, at **5.4% for Q3** and **5.4% for the nine-month period**, with operational growth of **6.5%** and **7.1%** respectively[2](index=2&type=chunk)[4](index=4&type=chunk) [Sales by Business Segment](index=3&type=section&id=Sales%20to%20customers%20by%20segment%20of%20business) Both Innovative Medicine and MedTech segments delivered strong operational growth, with underlying performance masked by declining COVID-19 vaccine sales Q3 2024 Sales by Business Segment (in Millions) | Segment | 2024 Sales | 2023 Sales | Total Change | Operational Change | | :--- | :--- | :--- | :--- | :--- | | Innovative Medicine | $14,580 | $13,893 | 4.9% | 6.3% | | MedTech | $7,891 | $7,458 | 5.8% | 6.4% | | **Worldwide** | **$22,471** | **$21,351** | **5.2%** | **6.3%** | Nine Months 2024 Sales by Business Segment (in Millions) | Segment | 2024 Sales | 2023 Sales | Total Change | Operational Change | | :--- | :--- | :--- | :--- | :--- | | Innovative Medicine | $42,632 | $41,037 | 3.9% | 5.5% | | MedTech | $23,669 | $22,727 | 4.1% | 5.7% | | **Worldwide** | **$66,301** | **$63,764** | **4.0%** | **5.6%** | - Excluding COVID-19 vaccine sales, the Innovative Medicine segment's worldwide sales grew **5.2% (6.6% operational) in Q3** and **6.2% (7.9% operational)** for the nine-month period[5](index=5&type=chunk)[6](index=6&type=chunk) [Condensed Consolidated Statement of Earnings](index=5&type=section&id=Condensed%20consolidated%20statement%20of%20earnings) Sales growth was offset by increased expenses, leading to mixed results between GAAP and Adjusted Net Earnings [Third Quarter 2024 Earnings](index=5&type=section&id=Third%20Quarter%202024%20Earnings) Q3 sales grew, but a surge in R&D expenses led to a significant decline in both GAAP and Adjusted Net Earnings Q3 2024 Statement of Earnings Highlights (in Millions, except per share) | Metric | 2024 | 2023 | % Change | | :--- | :--- | :--- | :--- | | Sales to customers | $22,471 | $21,351 | 5.2% | | Gross Profit | $15,508 | $14,745 | 5.2% | | R&D Expense | $4,952 | $3,447 | 43.7% | | Net Earnings from Continuing Operations (GAAP) | $2,694 | $4,309 | (37.5)% | | Diluted EPS from Continuing Operations (GAAP) | $1.11 | $1.69 | (34.3)% | | Adjusted Net Earnings from Continuing Operations (Non-GAAP) | $5,876 | $6,777 | (13.3)% | | Adjusted Diluted EPS from Continuing Operations (Non-GAAP) | $2.42 | $2.66 | (9.0)% | [Nine Months 2024 Earnings](index=6&type=section&id=Nine%20Months%202024%20Earnings) Year-to-date sales growth drove higher GAAP earnings, while Adjusted Net Earnings saw a slight decline Nine Months 2024 Statement of Earnings Highlights (in Millions, except per share) | Metric | 2024 | 2023 | % Change | | :--- | :--- | :--- | :--- | | Sales to customers | $66,301 | $63,764 | 4.0% | | Gross Profit | $45,958 | $44,009 | 4.4% | | R&D Expense | $11,934 | $10,605 | 12.5% | | Net Earnings from Continuing Operations (GAAP) | $10,635 | $9,194 | 15.7% | | Diluted EPS from Continuing Operations (GAAP) | $4.38 | $3.53 | 24.1% | | Adjusted Net Earnings from Continuing Operations (Non-GAAP) | $19,296 | $19,847 | (2.8)% | | Adjusted Diluted EPS from Continuing Operations (Non-GAAP) | $7.94 | $7.62 | 4.2% | [Reconciliation of Non-GAAP Financial Measures](index=7&type=section&id=Reconciliation%20of%20non-GAAP%20financial%20measures) This section details adjustments for special items to bridge GAAP earnings to non-GAAP operational performance [Reconciliation of Net Earnings (Q3 & Nine Months)](index=7&type=section&id=Reconciliation%20of%20Net%20Earnings) Significant adjustments for litigation and amortization were key in reconciling GAAP to non-GAAP net earnings Q3 2024 Reconciliation of Net Earnings (in Millions) | Description | Amount | | :--- | :--- | | Net Earnings from Continuing Operations (GAAP) | $2,694 | | Pre-tax Adjustments (Litigation, Amortization, etc.) | $3,921 | | Tax Impact on Adjustments | ($757) | | **Adjusted Net Earnings from Continuing Operations (Non-GAAP)** | **$5,876** | Nine Months 2024 Reconciliation of Net Earnings (in Millions) | Description | Amount | | :--- | :--- | | Net Earnings from Continuing Operations (GAAP) | $10,635 | | Pre-tax Adjustments (Litigation, Amortization, etc.) | $10,581 | | Tax Impact on Adjustments | ($2,097) | | **Adjusted Net Earnings from Continuing Operations (Non-GAAP)** | **$19,296** | - Restructuring activities include exiting certain R&D programs in Innovative Medicine and streamlining the Orthopaedics franchise in MedTech[16](index=16&type=chunk)[18](index=18&type=chunk) [Reconciliation of Adjusted Operational Sales Growth (Q3 & Nine Months)](index=9&type=section&id=Reconciliation%20of%20Adjusted%20Operational%20Sales%20Growth) Excluding currency, A&D, and vaccine impacts reveals stronger underlying operational sales growth Q3 2024 Adjusted Operational Sales Growth Reconciliation | Segment | Reported Growth | Operational Growth | Adjusted Operational Growth (Ex A&D, COVID-19) | | :--- | :--- | :--- | :--- | | Innovative Medicine | 4.9% | 6.3% | 6.7% | | MedTech | 5.8% | 6.4% | 3.7% | | **Total** | **5.2%** | **6.3%** | **5.6%** | Nine Months 2024 Adjusted Operational Sales Growth Reconciliation | Segment | Reported Growth | Operational Growth | Adjusted Operational Growth (Ex A&D, COVID-19) | | :--- | :--- | :--- | :--- | | Innovative Medicine | 3.9% | 5.5% | 8.0% | | MedTech | 4.1% | 5.7% | 4.7% | | **Total** | **4.0%** | **5.6%** | **6.8%** | [Detailed Segment Sales Analysis](index=11&type=section&id=Segment%20sales) A detailed review of the Innovative Medicine and MedTech segments highlights key product drivers and franchise performance [Innovative Medicine Segment](index=11&type=section&id=INNOVATIVE%20MEDICINE%20SEGMENT) Growth was driven by Oncology and Pulmonary Hypertension, offsetting declines in Immunology and COVID-19 vaccine sales [Third Quarter 2024 Performance](index=11&type=section&id=Innovative%20Medicine%20Third%20Quarter%202024%20Performance) Q3 growth was led by standout performance in the Oncology portfolio, particularly from DARZALEX and CARVYKTI Q3 2024 Key Product Sales (Worldwide, in Millions) | Product | 2024 Sales | % Change (Reported) | | :--- | :--- | :--- | | DARZALEX | $3,016 | 20.7% | | STELARA | $2,864 | (6.6)% | | TREMFYA | $891 | 13.0% | | ERLEADA | $790 | 25.4% | | CARVYKTI | $286 | 87.7% | - **Oncology** was the largest therapeutic area by sales in Q3, reaching **$5.38 billion**, a significant increase from $4.53 billion in the prior year[26](index=26&type=chunk) [Nine Months 2024 Performance](index=19&type=section&id=Innovative%20Medicine%20Nine%20Months%202024%20Performance) Year-to-date growth was fueled by Oncology, mitigating the impact of biosimilar competition and a steep vaccine sales drop Nine Months 2024 Key Product Sales (Worldwide, in Millions) | Product | 2024 Sales | % Change (Reported) | | :--- | :--- | :--- | | DARZALEX | $8,586 | 19.3% | | STELARA | $8,105 | (1.2)% | | TREMFYA | $2,237 | 21.6% | | ERLEADA | $2,215 | 27.3% | | CARVYKTI | $629 | 84.3% | - The decline in COVID-19 vaccine sales had a significant impact, with revenue dropping from over **$1 billion** in the first nine months of 2023 to just **$198 million** in 2024[40](index=40&type=chunk) [MedTech Segment](index=16&type=section&id=MEDTECH%20SEGMENT) Solid growth was driven by the Cardiovascular portfolio, boosted by Electrophysiology performance and the acquisition of Shockwave [Third Quarter 2024 Performance](index=16&type=section&id=MedTech%20Third%20Quarter%202024%20Performance) Q3 sales surged due to strong Cardiovascular results, including a significant contribution from the newly acquired Shockwave Q3 2024 MedTech Sales by Franchise (Worldwide, in Millions) | Franchise | 2024 Sales | % Change (Reported) | | :--- | :--- | :--- | | Cardiovascular | $1,966 | 26.2% | | Orthopaedics | $2,191 | 1.2% | | Surgery | $2,434 | (1.8)% | | Vision | $1,300 | 3.5% | - The acquisition of **Shockwave** on May 31, 2024, is a significant new contributor to the Cardiovascular franchise[28](index=28&type=chunk)[36](index=36&type=chunk) [Nine Months 2024 Performance](index=24&type=section&id=MedTech%20Nine%20Months%202024%20Performance) Year-to-date growth was led by the Cardiovascular franchise, with solid contributions from Orthopaedics Nine Months 2024 MedTech Sales by Franchise (Worldwide, in Millions) | Franchise | 2024 Sales | % Change (Reported) | | :--- | :--- | :--- | | Cardiovascular | $5,645 | 20.6% | | Orthopaedics | $6,843 | 2.5% | | Surgery | $7,338 | (2.2)% | | Vision | $3,843 | (0.5)% | [Supplemental Sales Information](index=27&type=section&id=Supplemental%20sales%20information%20(unaudited)) This section isolates the impact of COVID-19 vaccine sales to clarify the underlying growth of the company's core business [Impact of COVID-19 Vaccine Sales](index=27&type=section&id=Impact%20of%20COVID-19%20Vaccine%20Sales) Excluding the steep decline in COVID-19 vaccine revenue reveals stronger underlying operational sales growth for the company Q3 2024 Sales Excluding COVID-19 Vaccine (in Millions) | Metric | Including Vaccine | Excluding Vaccine | | :--- | :--- | :--- | | Worldwide Sales | $22,471 | $22,470 | | Total Growth | 5.2% | 5.4% | | Operational Growth | 6.3% | 6.5% | Nine Months 2024 Sales Excluding COVID-19 Vaccine (in Millions) | Metric | Including Vaccine | Excluding Vaccine | | :--- | :--- | :--- | | Worldwide Sales | $66,301 | $66,103 | | Total Growth | 4.0% | 5.4% | | Operational Growth | 5.6% | 7.1% |

Johnson & Johnson JNJ will release earnings results for its third quarter before the opening bell on Tuesday, Oct. 15.Analysts expect the New Brunswick, New Jersey-based bank to report quarterly earnings at $2.21 per share, down from $2.66 per share in the year-ago period. Johnson & Johnson projects to report revenue of $22.16 billion for the recent quarter, compared to $21.03 billion a year earlier, according to data from Benzinga Pro.On Oct. 9, Johnson & Johnson said it has completed acquisition of V-Wave ...

Johnson & Johnson (NYSE: JNJ ) , a global healthcare giant with roots going back to 1886, is set to drop its earnings report for the fiscal quarter ending September 2024. The company, known for its wide range of medical devices, pharmaceuticals, and consumerThe mission of Grassroots Trading rests on the following principles: providing objective, unbiased, and balanced research, backed by solid data and completely void of emotional influences or preference for companies; focusing on small- to mid-cap compani ...

CHINA - 2023/02/15: In this photo illustration, the American multinational medical devices and ... [+] pharmaceutical company Johnson & Johnson (J&J) logo is seen displayed on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesJohnson & Johnson stock (NYSE: JNJ) will report its Q3 2024 results on Tuesday, October 15. We expect the company to post revenue of $22.2 bi ...

Analyst Estimates for Q3 2024Q2 2024Q3 2023Revenue$22.18 billion$22.45 billion$21.35 billionDiluted EPS$1.80$1.93$1.69Net Income$4.38 billion$4.69 billion$4.31 billion Key Metric: Updated Outlook After V-Wave Adjustment The company has shifted its full-year outlook in each of its first two quarters, and recently said it expects to do so again. In the first quarter, the company narrowed its full-year sales and profit estimates, and in the second quarter lifted its sales estimates while lowering profit pro ...

I last wrote on Johnson & Johnson (NYSE: JNJ ) stock back in August 2024. In an article titled "Johnson & Johnson: Don't Bet Against Double Compounding ", I argued for a buy As you can tell, our core style is to provide actionable and unambiguous ideas from our independent research. If your share this investment style, check out Envision Early Retirement. It provides at least 1x in-depth articles per week on such ideas.We have helped our members not only to beat S&P 500 but also avoid heavy drawdowns despit ...

Analysts on Wall Street project that Johnson & Johnson (JNJ) will announce quarterly earnings of $2.19 per share in its forthcoming report, representing a decline of 17.7% year over year. Revenues are projected to reach $22.19 billion, increasing 3.9% from the same quarter last year.The consensus EPS estimate for the quarter has been revised 0.1% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during t ...

TREMFYA® is now U.S. FDA-approved for ulcerative colitis and under review for Crohn's disease TREMFYA® is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of patients with Crohn's disease, inclusive of those who are biologic-naïve and biologic-refractory Ninety percent more biologic-naïve patients and three times more biologic-refractory patients with ulcerative colitis achieved endoscopic remission with TREMFYA® VIENNA, Austria, Oct. 10, 2024 /PRNewswire/ -- John ...

Submission supported by data from the Phase 3 CEPHEUS study for the treatment of patients with newly diagnosed multiple myeloma for whom transplant is not planned as initial therapy1 Data showed that the daratumumab subcutaneous formulation-based quadruplet regimen significantly improved minimal residual disease (MRD)-negativity and reduced the risk of progression or death compared to standard of care regimen1 BEERSE, BELGIUM , Oct. 10, 2024 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a Johnson & J ...